# US 2021/0079050 A1 · Compositions and methods for delivery and expression of small inhibitory peptides and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079050 A1
- Document ID: US20210079050A1
- Status: Published application
- Kind: A1
- Application number: 16/971,234
- Filed: 2019-02-20
- Published: 2021-03-18
- Earliest claimed: 2018-02-20
- Assignees: Carmel-Haifa University Economic Corp. Ltd.
- Applicants: Carmel Haifa University Economic Corporation Ltd.
- Inventors: Kobi ROSENBLUM; Efrat EDRY
- Web page: https://patentgrep.com/patent/US20210079050A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/48: Nerve growth factor [NGF]
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2319/02: containing a signal sequence
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to, inter alia, a chimeric polynucleotide made up of a first polynucleotide encoding a specific cell predominantly expressed protein precursor and a second polynucleotide encoding a modulating-peptide. Further provided are methods for specific delivery of small modulating peptides to specific cells. Also provided are methods for treating cell-specific-associated diseases, including but not limited to, muscular, neural, hepatic and pancreatic disease, in a subject in need thereof.

## Claims

### Claim 1

A chimeric polynucleotide molecule comprising:
a. a first polynucleotide encoding a propeptide domain of a first polypeptide; and
b. a second polynucleotide encoding a second polypeptide of 2-50 amino acids having a modulating activity,
wherein said propeptide domain is a specific cell predominantly expressed protein precursor, and wherein said first polypeptide and said second polypeptide are not derived from the same gene and are operably linked.

### Claim 2 (depends on 1)

The chimeric polynucleotide molecule of claim 1, wherein said propeptide domain comprises a signal peptide sequence and a protease/convertase motif.

### Claim 3 (depends on 2)

The chimeric polynucleotide molecule of claim 2, wherein said signal peptide sequence and said protease/convertase motif are endogenous to said propeptide.

### Claim 4 (depends on 1)

The chimeric polynucleotide molecule of claim 1, wherein said modulating peptide is an endogenous peptide.

### Claim 5 (depends on 1)

The chimeric polynucleotide molecule of claim 1, wherein said modulating peptide is an exogenous peptide.

### Claim 6 (depends on 1)

The chimeric polynucleotide molecule of claim 1, wherein said modulating peptide is a synthetic peptide.

### Claim 7 (depends on 1)

The chimeric polynucleotide molecule of claim 1, wherein said propeptide domain is encoded by a polynucleotide sequence as set forth in SEQ ID NO:1 or SEQ ID NO: 2.

### Claim 8 (depends on 1)

A delivery vector for expression of the chimeric polynucleotide of claim 1.

### Claim 9 (depends on 1, 8)

The delivery vector of claim 8, comprising a promoter polynucleotide for driving the expression of the chimeric polynucleotide of claim 1 predominantly in a specific cell.

### Claim 10 (depends on 9)

The delivery vector of claim 9, wherein said specific cell is selected from the group consisting of a neural cell, a muscle cell, a liver cell, and a pancreas cell.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 8)

The delivery vector of claim 8, wherein the first polynucleotide sequence encoding the propeptide domain of the first polypeptide is selected from the group consisting of neurotrophic factors.

### Claim 15 (depends on 8)

The delivery vector of claim 8, wherein the first polynucleotide sequence encoding the propeptide domain of the first polypeptide is selected from the group consisting of procollagens, is polypeptide derived from factor X, proinsulin, proglucagon, pro somatostatin, and proghrelin.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 8)

A cell comprising the delivery vector of claim 8, wherein said cell is selected from the group consisting of: sensory neurons, motor neurons, interneurons, neurons of the brain, astrocytes, microglia, ependymal cells, oligodendrocytes, Schwann cells, satellite cells, enteric glial cells, olfactory cells, and sheathing cells.

### Claim 23 (depends on 8)

A cell comprising the delivery vector of claim 8, wherein said cell is selected from: (i) a cell selected from the group consisting of: red skeletal muscle cell, white skeletal muscle cell, intermediate muscle cell, nuclear bag cell, nuclear chain cell, satellite cell, heart muscle cell, nodal heart muscle cell, Purkinje fiber cell, smooth muscle cell, and myoepithelial cell; (ii) a cell selected from the group consisting of: hepatocyte, Kupffer cell, and liver stellate cell; (iii) a cell selected from the group consisting of: Alpha cell, Beta cell, Delta cell, Gamma cell, and Epsilon, cell; (iv) a cell selected from the group consisting of: Alpha cell, Beta cell, Delta cell, Gamma cell, and Epsilon cell.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A chimeric polypeptide encoded by the chimeric polynucleotide of claim 1.

### Claim 27 (depends on 1)

A method for modulating a specific cell, comprising the step of contacting the specific cell with the chimeric polynucleotide of claim 1 thereby modulating the specific cell.

### Claim 28 (depends on 27)

The method of claim 27, wherein said contacting the specific cell comprises the step of systemically administering to a subject in need thereof said chimeric polynucleotide, thereby producing post-translationally active modulating peptide only in a specific cell of the subject, thereby modulating only the specific cell of the subject.

### Claim 29 (depends on 1)

A method for treating cell-specific-associated disease or disorder in a subject in need thereof, the method comprising administering to the subject the chimeric polynucleotide of claim 1 thereby treating cell-specific-associated disease in the subject.

### Claim 30 (depends on 29)

The method of claim 29, wherein said cell-specific is selected from a neural cell, a muscle cell, a liver cell, and a pancreas cell.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 30)

The method of claim 30, wherein said disease or disorder is selected from the group consisting of: degenerative disease, developmental disease or cancer disease.
